Biotech ImmunoGen Stock Jumps 140% After Positive Drug Trial Data

ImmunoGen’s shares soared 136% on Wednesday after the biotech company reported “significant and clinically meaningful” survival results in a phase 3 trial of its Elahere treatment among patients with ovarian cancer.#immunogen
Source: Reuters: Health - Category: Consumer Health News Source Type: news